Innocan Pharma's Liposome Platform Technology Demonstrates a 7-Week Prolonged Release of CBD into Bloodstream in Recent Animal Study
Herzliya, Israel and Calgary Alberta--(Newsfile Corp. - June 11, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that a recent study conducted on mice demonstrated a prolonged release of cannabidiol (CBD) into the animals' bloodstream for at least 7 weeks following local two injections. Innocan believes this result to be extremely encouraging, given the 24-hour maximum CBD presence in the bloodstream when...
2021-06-11 3:00 AM EDT
Innocan Pharma Among Leading CBD Pharma Companies to Participate at Lytham Partners Summer 2021 Investor Conference
Israel and Calgary, Alberta--(Newsfile Corp. - June 9, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that it will participate at the Lytham Partners Summer 2021 Investor Conference on June 14 through June 16, 2021. Iris Bincovich, CEO of Innocan will participate on the "CBD Treatments" discussion panel alongside representatives from cbdMD, Charlotte's Web, CV Science Inc, and Avicanna on Monday June 14 at 11:00AM...
2021-06-09 4:00 PM EDT
Innocan Pharma's CBD Loaded Liposome Platform Technology Receives Positive Results from Recent Animal Study
Israel and Calgary, Alberta--(Newsfile Corp. - May 14, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce today that a recent study conducted in mice based on Innocan's licensed CBD-loaded liposome platform technology (LPT) for injectable CDB solutions demonstrated a prolonged release of cannabidiol (CBD) into the mice's' bloodstream for at least 50 days following two injections. This study was led by Dr. Ahuva Cern, a...
2021-05-14 3:28 AM EDT
Innocan Pharma Engages Lytham Partners to Lead Investor Relations and Shareholder Communication Program
Israel and Calgary, Alberta--(Newsfile Corp. - May 10, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") today announced it has retained Lytham Partners, LLC ("Lytham Partners") to lead an investor relations and shareholder communication program.For more than 20 years, Lytham Partners has been one of the industry's leading investor relations firms, having created one of the largest and most diverse networks of institutional investors, while...
2021-05-10 4:00 PM EDT
Innocan Pharma Announces Trading on the OTCQB Venture Market and DTC Eligibility of Its Common Shares in the United States
Israel and Calgary, Alberta--(Newsfile Corp. - May 6, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it is currently trading on the OTCQB Venture Market and is eligible for electronic clearing and settlement through The Depository Trust Company ("DTC") in the United States. The Company's common shares are quoted in the United States on the OTCQB Venture Market under the ticker symbol " INNPF ".
2021-05-06 8:26 AM EDT
Innocan Pharma and Polyflame Announce an Exclusive Distribution Agreement in France
Israel and Calgary, Alberta--(Newsfile Corp. - April 22, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the signing of a wide-scope commercial distribution agreement with Polyflame Europe. As part of the multi-year agreement, Polyflame Europe will enjoy an exclusive right to distribute both of Innocan's SHIR and Relief & Go brands in France based on a purchase forecast of 600,000 [EUR] per year in the first year...
2021-04-22 3:00 AM EDT
Richard Serbin, Former Johnson & Johnson's VP and a Leading Global Strategy Advisor in the Healthcare Industry, to Join Innocan Pharma's Scientific Advisory Committee
Israel and Calgary, Alberta--(Newsfile Corp. - April 6, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is proud to announce the addition of Richard Serbin to its Advisory Committee. Richard Serbin will work closely with Innocan's leadership to address the emerging global Pharma opportunities, to expand Innocan's presence as part of its growth strategy, and to contribute from his extensive experience as Johnson & Johnson's Executive Vice...
2021-04-06 4:00 PM EDT
Innocan Reports Q4 2020 Financial Results
Israel and Calgary, Alberta--(Newsfile Corp. - April 1, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce today its financial results and business highlights for the fourth quarter and year period ended December 31, 2020 and provide highlights and comments on these results. This news release should be read in conjunction with the Company's audited financial statements for this period (the "Financial Statements") and...
2021-04-01 3:00 AM EDT
Leading American Dermatologist Dr. Mitchell Kline to Join Innocan Pharma's Scientific Advisory Committee
Israel and Calgary, Alberta--(Newsfile Corp. - March 23, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan") is proud to announce the addition of Dr. Mitchell Kline to its Scientific Advisory Committee. Dr. Kline will serve as an active member of Innocan's R&D team, using his extensive experience in researching and treating different skin conditions, to further develop Innocan's derma cosmetic line.
2021-03-23 4:00 AM EDT
Innocan Pharma Announces Proceeds of CDN $ 3.1M from the Exercise of Warrants Since January 1, 2021
Israel and Calgary, Alberta--(Newsfile Corp. - March 16, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan") today announces that since January 1, 2021, it has received proceeds of approximately CDN $3.1M as a result of the exercise of approximately 11.9 million previously issued common share purchase warrants (the "IPO Warrants") and certain broker warrants.Pursuant to the terms of the IPO Warrants, the Company's volume weighted average...
2021-03-16 4:20 PM EDT
Innocan Pharma Announces Patent Application for Novel Cannabis-Based Anti-Itch Treatment
Israel and Calgary, Alberta--(Newsfile Corp. - March 10, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan") filed an international patent application for a novel cannabis-based Anti-itch treatment. The composition is comprised of a pharmaceutically effective amount of a cannabinoid and active ingredients to aid in the relief of itching associated with insect bites, rash, cuts, burns or by exposure to various allergens.
2021-03-10 3:00 AM EST
Innocan Pharma Announces the Completion of its First Full-Scale Manufacturing Run in the US and the Launching of its US Commercial Online Platform
Israel and Calgary, Alberta--(Newsfile Corp. - February 22, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan"), is pleased to announce the completion of its first full and large-scale commercial production of its SYNONY premium cosmetic line and Relief &Go OTC pain relief spray in the United States and the launch of its US Commercial Website.Innocan has successfully completed its first commercial manufacturing run in the US of 40,000 Units...
2021-02-22 4:00 PM EST
Innocan Pharma Announces Proceeds of CDN $ 1.8M from the Exercise of Warrants Since December 1, 2020
Israel and Calgary, Alberta--(Newsfile Corp. - January 28, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan") today announces that since December 1, 2020, it has received proceeds of approximately CDN $1.8M as a result of the exercise of approximately 7.6 Million previously issued common share purchase warrants and broker warrants. "The exercise of the warrants," states CEO Iris Bincovich, "Indicates that investors are confident in InnoCan...
2021-01-28 4:00 PM EST
Innocan Pharma Announces Successful Production of CBD Loaded Liposomes under Aseptic Conditions
Israel and Calgary, Alberta--(Newsfile Corp. - January 22, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC PINK: INNPF) (the "Company" or "Innocan"), is pleased to announce today a successful manufacturing demonstration of liposome platform technology ("LPT") CBD-loaded Liposomes under aseptic conditions, together with the Hebrew University of Jerusalem. This is an important milestone in the production process of CBD-loaded Liposomes, as it now permits the demonstration of...
2021-01-22 2:00 AM EST
Innocan Pharma Successfully Completes Large Scale Production of Exosomes
Israel and Calgary, Alberta--(Newsfile Corp. - January 14, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan"), is pleased to announce the successful completion of a large-scale production of exosomes. Innocan's CBD Loaded Exosome (CLX) Therapy project led by Prof. Offen demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process. Innocan managed to...
2021-01-14 4:00 PM EST
Innocan Pharma Announces the Launch of Its Commercial Website
Israel and Calgary, Alberta--(Newsfile Corp. - January 5, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan"), is pleased to announce the launch of its commercial web-platform, shop.innocanpharma.com. The Company, through its wholly owned subsidiary, Innocan Pharma Ltd. ("Innocan Israel"), has signed certain agreements with world leading companies for the fulfillment, logistics, and service of the website. The new website has been designed...
2021-01-05 3:00 AM EST
Innocan Pharma Announces Closing of Private Placement
Israel and Calgary, Alberta--(Newsfile Corp. - December 31, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has today closed a non-brokered private placement offering of 10,294,800 units of Innocan (the "Units") at a price of $0.23 per Units for aggregate gross proceeds of $2,367,804 (the "Offering").All Common Shares and Warrants issued pursuant to the Offering will be subject to a four month statutory hold...
2020-12-31 8:30 AM EST
Innocan Pharma Announces the Successful Completion of Its First Full-Scale Manufacturing Run in Europe and the Commencement of Its Full-Scale Manufacturing Run in the USA
Israel and Calgary, Alberta--(Newsfile Corp. - December 16, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan"), is pleased to announce the completion of its first commercial production of the Shir premium cosmetic line and Relief & Go topicals in Portugal and is pleased to announce the commencement of production in the United States, for the first time.Innocan has successfully completed its first commercial manufacturing run of in...
2020-12-16 4:00 PM EST
Innocan Pharma Completes Its Trademark Registration in the EU, UK and Switzerland
Israel and Calgary, Alberta--(Newsfile Corp. - December 10, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan"), is pleased to announce the completion of the registration of its trademarks: Innocan Pharma, Relief & Go and SHIR in the EU, UK and Switzerland. These trademarks represent Innocan's OTC and derma cosmetic brand products that were recently launched in the German and UK markets.
2020-12-10 4:00 PM EST
Innocan Pharma to Participate in the Lytham Partners End of Year 1x1 Conference
Israel and Calgary, Alberta--(Newsfile Corp. - December 3, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that it was invited by one of the leading IR agencies in the U.S., Lytham Partners, to participate in its End of Year 1x1 Conference (the "Conference") from December 7-11, 2020. CEO Iris Bincovich will be participating on behalf of Innocan and will showcase the Company in one-on-one meetings at the Conference. To...
2020-12-03 4:00 PM EST